Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,542 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA, Fasching PA, Couch FJ, Balmaña J, Delaloge S, Labidi-Galy I, Bennett J, McCutcheon S, Walker G, O'Shaughnessy J; Collaborating Investigators. Gelmon KA, et al. Among authors: bennett j. Eur J Cancer. 2021 Jul;152:68-77. doi: 10.1016/j.ejca.2021.03.029. Epub 2021 Jun 1. Eur J Cancer. 2021. PMID: 34087573 Free article. Clinical Trial.
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.
Poveda A, Lheureux S, Colombo N, Cibula D, Lindemann K, Weberpals J, Bjurberg M, Oaknin A, Sikorska M, González-Martín A, Madry R, Pérez MJR, Ledermann J, Davidson R, Blakeley C, Bennett J, Barnicle A, Škof E. Poveda A, et al. Among authors: bennett j. Gynecol Oncol. 2022 Mar;164(3):498-504. doi: 10.1016/j.ygyno.2021.12.025. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063276 Free article. Clinical Trial.
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Cadoo K, Simpkins F, Mathews C, Liu YL, Provencher D, McCormick C, ElNaggar AC, Altman AD, Gilbert L, Black D, Kabil N, Bennett J, Munley J, Aghajanian C. Cadoo K, et al. Among authors: bennett j. Gynecol Oncol. 2022 Sep;166(3):425-431. doi: 10.1016/j.ygyno.2022.06.017. Epub 2022 Jul 5. Gynecol Oncol. 2022. PMID: 35803835 Free PMC article. Clinical Trial.
Comparison of Prophylactic Intravenous Antibiotic Regimens After Endoprosthetic Reconstruction for Lower Extremity Bone Tumors: A Randomized Clinical Trial.
Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Investigators; Ghert M, Schneider P, Guyatt G, Thabane L, Vélez R, O'Shea T, Randall RL, Turcotte R, Wilson D, Wunder JS, Baptista AM, Cheng EY, Doung YC, Ferguson PC, Giglio V, Hayden J, Heels-Ansdell D, Khan SA, Sampath Kumar V, McKay P, Miller B, van de Sande M, Zumárraga JP, Bhandari M. Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) Investigators, et al. JAMA Oncol. 2022 Mar 1;8(3):345-353. doi: 10.1001/jamaoncol.2021.6628. JAMA Oncol. 2022. PMID: 34989778 Free PMC article. Clinical Trial.
Evaluation of a novel university-based testing platform to increase access to SARS-CoV-2 testing during the COVID-19 pandemic in a cohort study.
Bennett JC, O'Hanlon J, Acker Z, Han PD, McDonald D, Wright T, Luiten KG, Regelbrugge L, McCaffrey KM, Pfau B, Wolf CR, Gottlieb GS, Hughes JP, Carone M, Starita LM, Chu HY, Weil AA. Bennett JC, et al. BMJ Open. 2024 Jun 4;14(6):e081837. doi: 10.1136/bmjopen-2023-081837. BMJ Open. 2024. PMID: 38834321 Free article.
5,542 results